Charged-Particle Therapy for Hepatocellular Carcinoma

Seminars in Radiation Oncology

Volumn 21, Issue 4, 2011, Pages 278-286

  Skinner, Heath D ^a   Hong, Theodore S ^b   Krishnan, Sunil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE DUCT CARCINOMA; CANCER CONTROL; CHARGED PARTICLE THERAPY; DOSIMETRY; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION INJURY; RADIOTHERAPY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARBON; CARCINOMA, HEPATOCELLULAR; HUMANS; IONS; LIVER NEOPLASMS; PARTICLE ACCELERATORS; PROTONS;

EID: 80052977888     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.05.007     Document Type: Review

References (42)

1. Bosch F.X., Ribes J., Díaz M., et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004, 127(suppl 1):S5-S16.
2. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
3. Seong J., Park H.C., Han K.H., et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003, 55:329-336.
4. Park H.C., Seong J., Han K.H., et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:150-155.
5. Wang X., Krishnan S., Zhang X., et al. Proton radiotherapy for liver tumors: Dosimetric advantages over photon plans. Med Dosim 2008, 33:259-267.
6. Taddei P.J., Howell R.M., Krishnan S., et al. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol 2010, 55:7055-7065.
7. Gerweck L.E., Kozin S.V. Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol 1999, 50:135-142.
8. Dale R.G., Jones B., Cárabe-Fernández A. Why more needs to be known about RBE effects in modern radiotherapy. Appl Radiat Isot 2009, 67:387-392.
9. Kato H., Tsujii H., Miyamoto T., et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis1, 1. Int J Radiat Oncol Biol Phys 2004, 59:1468-1476.
10. Ando K., Kase Y. Biological characteristics of carbon-ion therapy. Int J Radiat Biol 2009, 85:715-728.
11. Carabe-Fernandez A., Dale R.G., Hopewell J.W., et al. Fractionation effects in particle radiotherapy: Implications for hypo-fractionation regimes. Phys Med Biol 2010, 55:5685-5700.
12. Raju M.R. Heavy-particle studies with silicon detectors. Radiat Res Suppl 1967, 7:43-52.
13. Ando K., Koike S., Ohira C., et al. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 1999, 75:505-512.
14. Wilson R.R. Radiological use of fast protons. Radiology 1946, 47:487-491.
15. Miller D.W. A review of proton beam radiation therapy. Med Phys 1995, 22:1943-1954.
16. Cheung J., Kudchadker R.J., Zhu X.R., et al. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer. Phys Med Biol 2010, 55:7135-7147.
17. Case R.B., Sonke J.J., Moseley D.J., et al. Inter- and intrafraction variability in liver position in non-breath-hold stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:302-308.
18. Casse B.D., Lu W.T., Banyal R.K., et al. Imaging with subwavelength resolution by a generalized superlens at infrared wavelengths. Opt Lett 2009, 34:1994-1996.
19. Wunderink W., Mendez-Romero A., Seppenwoolde Y., et al. Potentials and limitations of guiding liver stereotactic body radiation therapy set-up on liver-implanted fiducial markers. Int J Radiat Oncol Biol Phys 2010, 77:1573-1583.
20. Kothary N., Heit J.J., Louie J.D., et al. Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. J Vasc Interv Radiol 2009, 20:235-239.
21. Xi M., Liu M.-Z., Deng X.-W., et al. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol 2007, 84:272-278.
22. Beddar A.S., Briere T.M., Balter P., et al. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol 2008, 87:445-448.
23. Hawkins M.A., Brock K.K., Eccles C., et al. Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. Int J Radiat Oncol Biol Phys 2006, 66:610-619.
24. Fuss M., Salter B.J., Cavanaugh S.X., et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys 2004, 59:1245-1256.
25. Dawson L.A., Brock K.K., Kazanjian S., et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys 2001, 51:1410-1421.
26. Dawson L.A., Eccles C., Bissonnette J.P., et al. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005, 62:1247-1252.
27. Eccles C.L., Patel R., Simeonov A.K., et al. Comparison of liver tumor motion with and without abdominal compression using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2011, 79:602-608.
28. Briere T.M., Beddar S., Balter P., et al. Respiratory gating with EPID-based verification: The MDACC experience. Phys Med Biol 2009, 54:3379-3391.
29. Guckenberger M., Sweeney R.A., Wilbert J., et al. Image-guided radiotherapy for liver cancer using respiratory-correlated computed tomography and cone-beam computed tomography. Int J Radiat Oncol Biol Phys 2008, 71:297-304.
30. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53:810-821.
31. Chiba T., Tokuuye K., Matsuzaki Y., et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 2005, 11:3799-3805.
32. Mizumoto M., Tokuuye K., Sugahara S., et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 2008, 71:462-467.
33. Hata M., Tokuuye K., Sugahara S., et al. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006, 107:591-598.
34. Hata M., Tokuuye K., Sugahara S., et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2005, 104:794-801.
35. Hata M., Tokuuye K., Sugahara S., et al. Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:805-812.
36. Sugahara S., Oshiro Y., Nakayama H., et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010, 76:460-466.
37. Nakayama H., Sugahara S., Tokita M., et al. Proton beam therapy for hepatocellular carcinoma: The University of Tsukuba experience. Cancer 2009, 115:5499-5506.
38. Fukumitsu N., Sugahara S., Nakayama H., et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:831-836.
39. Sugahara S., Nakayama H., Fukuda K., et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 2009, 185:782-788.
40. Hashimoto T., Tokuuye K., Fukumitsu N., et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:196-202.
41. Kawashima M., Furuse J., Nishio T., et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005, 23:1839-1846.
42. Bush D.A., Hillebrand D.J., Slater J.M., et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. Gastroenterology 2004, 127:S189-S193.